Cargando…

BNT162b2 Effectiveness Against Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2 in Adolescents Aged 12–17 Years, by Dosing Interval and Duration

BACKGROUND: Two- and 3-dose BNT162b2 vaccine effectiveness (VE) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, including Delta and Omicron variants, was assessed among adolescents in Canada, where first and second doses were spaced longer than the manufacturer-specif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ionescu, Iulia G, Skowronski, Danuta M, Sauvageau, Chantal, Chuang, Erica, Ouakki, Manale, Kim, Shinhye, De Serres, Gaston
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132765/ https://www.ncbi.nlm.nih.gov/pubmed/36645782 http://dx.doi.org/10.1093/infdis/jiad006

Ejemplares similares

Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study
por: Carazo, Sara, et al.
Publicado: (2023)

Measles in Canada Between 2002 and 2013
por: De Serres, Gaston, et al.
Publicado: (2015)

Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA–Vaccinated and Nonvaccinated Individuals in Quebec, Canada
por: Carazo, Sara, et al.
Publicado: (2022)

Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later – an exploratory study
por: Gilca, Vladimir, et al.
Publicado: (2018)

Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada
por: Skowronski, Danuta M, et al.
Publicado: (2022)

Impact of vaccine delays at the 2, 4, 6 and 12 month visits on incomplete vaccination status by 24 months of age in Quebec, Canada
por: Kiely, Marilou, et al.
Publicado: (2018)

SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time Since Vaccination: Test-Negative Design, British Columbia, Canada
por: El Adam, Shiraz, et al.
Publicado: (2022)

Seroconversion to Seasonal Influenza Viruses after A(H1N1)pdm09 Virus Infection, Quebec, Canada
por: Baz, Mariana, et al.
Publicado: (2012)

Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine
por: Leung, Nancy H L, et al.
Publicado: (2022)

Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants
por: Tartof, Sara Y, et al.
Publicado: (2022)

Effect of vaccine dosing intervals on Omicron surrogate neutralization after three doses of BNT162b2
por: Prusinkiewicz, Martin A., et al.
Publicado: (2023)

Human Papilloma Virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada
por: Sauvageau, Chantal, et al.
Publicado: (2007)

Introduction of the BNT162b2 vaccine during a COVID-19 nursing home outbreak
por: McEllistrem, M. Catherine, et al.
Publicado: (2021)

Immune Senescence Markers Predict the Cellular Immune Response to BNT162b2 Vaccination in Hemodialysis Patients
por: Van Praet, Jens T, et al.
Publicado: (2022)

SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses
por: Chatterjee, Debashree, et al.
Publicado: (2022)

School Absenteeism As an Adjunct Surveillance Indicator: Experience during the Second Wave of the 2009 H1N1 Pandemic in Quebec, Canada
por: Kom Mogto, Christelle Aïcha, et al.
Publicado: (2012)

Other Respiratory Viruses Are Important Contributors to Adult Respiratory Hospitalizations and Mortality Even During Peak Weeks of the Influenza Season
por: Gilca, Rodica, et al.
Publicado: (2014)

BNT162b2 Protection against the Omicron Variant in Children and Adolescents
por: Price, Ashley M., et al.
Publicado: (2022)

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
por: Cele, Sandile, et al.
Publicado: (2021)

Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
por: Yamamoto, Shohei, et al.
Publicado: (2023)

Risk of hospital admission and death from first-ever SARS-CoV-2 infection by age group during the Delta and Omicron periods in British Columbia, Canada
por: Skowronski, Danuta M., et al.
Publicado: (2023)

Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents
por: Reis, Ben Y., et al.
Publicado: (2021)

BNT162b2 Vaccine Effectiveness in Preventing Asymptomatic Infection With SARS-CoV-2 Virus: A Nationwide Historical Cohort Study
por: Zacay, Galia, et al.
Publicado: (2021)

Immune Response Kinetics Following a Third Heterologous BNT162b2 Booster Dose After Primary 2-Dose ChAdOx1 Vaccination in Relation to Omicron Breakthrough Infection: A Prospective Nationwide Cohort Study in South Korea
por: Ahn, Jin Young, et al.
Publicado: (2023)

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
por: Pérez-Then, Eddy, et al.
Publicado: (2022)

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
por: Collie, Shirley, et al.
Publicado: (2021)

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2022)

Human respiratory syncytial virus and other viral infections in infants receiving palivizumab
por: Boivin, Guy, et al.
Publicado: (2008)

Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication
por: Tani, Naoki, et al.
Publicado: (2022)

Relative Effectiveness of BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines and Homologous Boosting in Preventing COVID-19 in Adults in the US
por: Hung Nguyen, Van, et al.
Publicado: (2023)

Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers
por: Coggins, Si’Ana A, et al.
Publicado: (2021)

Physical, Psychological, and Cognitive Profile of Post-COVID Conditions in Healthcare Workers, Quebec, Canada
por: Carazo, Sara, et al.
Publicado: (2022)

Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022
por: Veneti, Lamprini, et al.
Publicado: (2023)

Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age
por: Khan, Farid L., et al.
Publicado: (2022)

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
por: Nemet, Ital, et al.
Publicado: (2021)

BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Extended interval BNT162b2 vaccination enhances peak antibody generation
por: Parry, Helen, et al.
Publicado: (2022)

Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation
por: Peled, Yael, et al.
Publicado: (2022)

Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa
por: Collie, Shirley, et al.
Publicado: (2022)

Role of Egg-adaptation Mutations in Low Influenza A(H3N2) Vaccine Effectiveness During the 2012–2013 Season
por: Skowronski, Danuta M, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_i348usev60ltc69a9r3llut4qd